Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleThe State of the Art

Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders

John P. Seibyl
Journal of Nuclear Medicine January 2023, 64 (1) 12-19; DOI: https://doi.org/10.2967/jnumed.122.264773
John P. Seibyl
Institute for Neurodegenerative Disorders, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 64 no. 1 12-19
DOI 
https://doi.org/10.2967/jnumed.122.264773
PubMed 
36302659

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication August 7, 2022
  • Revision received September 28, 2022
  • Published online January 4, 2023.

Article Versions

  • previous version (October 27, 2022 - 12:56).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. John P. Seibyl
  1. Institute for Neurodegenerative Disorders, New Haven, Connecticut
  1. For correspondence or reprints, contact John P. Seibyl (jseibyl{at}indd.org).
View Full Text

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: October 2022 to February 2023

AbstractFullPdf
Oct 2022955025
Nov 20221208035
Dec 2022269012
Jan 202318959495
Feb 202343128735
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (1)
Journal of Nuclear Medicine
Vol. 64, Issue 1
January 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders
John P. Seibyl
Journal of Nuclear Medicine Jan 2023, 64 (1) 12-19; DOI: 10.2967/jnumed.122.264773

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders
John P. Seibyl
Journal of Nuclear Medicine Jan 2023, 64 (1) 12-19; DOI: 10.2967/jnumed.122.264773
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • THE CHALLENGE OF DEVELOPING DRUGS FOR NEURODEGENERATIVE DISORDERS
    • DEVELOPING IMAGING BIOMARKERS
    • ISSUES AND CONTROVERSIES
    • QUANTITATIVE PET OUTCOME MEASURES
    • PET VISUAL READS
    • CORRELATION WITH CLINICAL MEASURES
    • COMPLEMENTARITY AND INTEGRATION OF BIOMARKERS IN CLINICAL TRIALS
    • FUTURE OUTLOOK AND RELEVANCE TO CLINICAL PRACTICE
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem
  • Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
Show more The State of the Art

Similar Articles

Keywords

  • PET
  • drug development
  • Alzheimer disease
  • Parkinson disease
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire